In the first study to examine the influence of statin medication on RCC progression, use of statins was associated with reduced risk of progression and mortality among 2,608 patients treated surgically for localized RCC. Over a median follow-up period of 36 months, a significant reduction in the risk of progression (HR 0.67) was seen with statin use, along with a nonsignificant reduction in overall mortality (HR 0.89). Modelling statin use as a time-dependent covariate (to account for the duration of statin treatment following surgery) altered risk reductions for both progression (HR 0.77) and mortality (HR 0.71).